RayKnowChina Research Map
Shortlist0

ShanghaiTongji University

Shanghai Tenth People's Hospital

上海市第十人民医院

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanghai Tenth People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  2. Hepatocellular carcinoma肝细胞癌27 papers led
  3. Stomach cancer胃癌21 papers led
  4. Hepatoblastoma肝母细胞瘤3 papers led
  5. Chordoma脊索瘤0 papers led
  6. Osteosarcoma骨肉瘤20 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  8. Neuroblastoma神经母细胞瘤2 papers led
  9. Ewing sarcoma尤文肉瘤0 papers led
  10. Multiple myeloma多发性骨髓瘤5 papers led
  11. Takayasu arteritis大动脉炎2 papers led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led

Not listed for: Nasopharyngeal carcinoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapyEarly detection & endoscopy
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 27 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 7720222023: 7720232024: 6620242025: 332025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsHepatitis B & cirrhosis
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led27
  1. USP21 stabilizes immune checkpoint of CD276 and serves as an immunological and tumor prognostic biomarker.2025Biochemical and biophysical research communications
  2. Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Liver ischemia-reperfusion promotes tumor metastasis via neutrophil-endothelial interactions: targeting ICAM1 to prevent metastatic recurrence.2025Journal of translational medicineFree full text
  4. TRIM65/NF2/YAP1 Signaling Coordinately Orchestrates Metabolic and Immune Advantages in Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Investigating the diagnostic and prognostic significance of genes related to fatty acid metabolism in hepatocellular carcinoma.2024BMC gastroenterologyFree full text
  6. TRIM47-CDO1 axis dictates hepatocellular carcinoma progression by modulating ferroptotic cell death through the ubiquitin‒proteasome system.2024Free radical biology & medicine
  7. Exploring the Role of DNA Methylation Located in Cuproptosis-Related Genes: Implications for Prognosis and Immune Landscape in Hepatocellular Carcinoma.2024Frontiers in bioscience (Landmark edition)
  8. ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.2024Hepatology (Baltimore, Md.)
  9. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.2024Journal of cellular and molecular medicineFree full text
  10. Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation.2023BMC cancerFree full text
  11. Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma.2023BioMed research internationalFree full text
  12. Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint.2023Environmental research
  13. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.2023Journal of experimental & clinical cancer research : CRFree full text
  14. Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma.2023Metabolism: clinical and experimental
  15. A systems biology-based approach to screen key splicing factors in hepatocellular carcinoma.2023Molecular carcinogenesis
  16. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.2023World journal of surgical oncologyFree full text
  17. The therapeutic potential of exosomes derived from different cell sources in liver diseases.2022American journal of physiology. Gastrointestinal and liver physiologyFree full text
  18. Circ_0000854 regulates the progression of hepatocellular carcinoma through miR-1294 /IRGQ axis.2022Clinical immunology (Orlando, Fla.)
  19. Hypomethylation of Thyroid Peroxidase as a Biomarker for Hepatocellular Carcinoma with Tumor Thrombosis.2022Current medical science
  20. The Transcription of ZIP9 Is Associated With the Macrophage Polarization and the Pathogenesis of Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  21. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway.2022Journal of cellular and molecular medicineFree full text
  22. Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-AKT signaling pathway.2022Journal of translational medicineFree full text
  23. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.2022Technology in cancer research & treatmentFree full text
  24. Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach.2021Current molecular medicine
  25. m6A mRNA Methylation Regulates LKB1 to Promote Autophagy of Hepatoblastoma Cells through Upregulated Phosphorylation of AMPK.2021GenesFree full text
  26. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.2021Journal of cellular and molecular medicineFree full text
  27. IFNγ-mediated repression of system xc- drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells.2021Journal of leukocyte biology
All its trials on ClinicalTrials.gov, any status2
  1. B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular CarcinomaStatus unknownNCT05070156Lead (inferred)Early phase 1Start 2021-10
  2. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 6620222023: 3320232024: 101020242025: 002025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07366528

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai

  2. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNutrition & recoverySurgeryImaging & AI
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led21
  1. Modeling human gastric cancers in immunocompetent mice.2024Cancer biology & medicineFree full text
  2. Characteristics and prognostic impact of cancer cachexia defined by the Asian Working Group for Cachexia consensus in patients with curable gastric cancer.2024Clinical nutrition (Edinburgh, Scotland)
  3. Comparison between AWGC-cachexia and GLIM-malnutrition in patients with gastric cancer.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. Single-cell analysis uncovers high-proliferative tumour cell subtypes and their interactions in the microenvironment of gastric cancer.2024Journal of cellular and molecular medicineFree full text
  5. Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression.2024Nature communicationsFree full text
  6. Muscle attenuation, not skeletal muscle index, is an independent prognostic factor for survival in gastric cancer patients with overweight and obesity.2024Nutrition (Burbank, Los Angeles County, Calif.)
  7. Differential cytokine expression in gastric tissues highlights helicobacter pylori's role in gastritis.2024Scientific reportsFree full text
  8. A cofactor-induced repressive type of transcription factor condensation can be induced by synthetic peptides to suppress tumorigenesis.2024The EMBO journalFree full text
  9. The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer.2024The Journal of clinical investigationFree full text
  10. Metabolic and immune-related gene signatures: Predictive stratification and prognostic implications in gastric cancer.2024The journal of gene medicine
  11. The Hippo signaling pathway in gastric cancer.2023Acta biochimica et biophysica SinicaFree full text
  12. Comparison of laparoscopic and open radical gastrectomy for gastric cancer patients with GLIM-defined malnutrition.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. METTL3-mediated m6A modification of lncRNA SNHG3 accelerates gastric cancer progression by modulating miR-186-5p/cyclinD2 axis.2023International journal of immunopathology and pharmacologyFree full text
  14. Cachexia Versus Sarcopenia in Clinical Characteristics and Prognostic Value After Radical Gastrectomy for Gastric Cancer: A Large-Scale Prospective Study.2022Annals of surgical oncology
  15. ASO Author Reflections: Comparison of Sarcopenia and Cachexia for Their Prognostic Value in Gastric Cancer Patients at Different TNM Stages After Gastrectomy.2022Annals of surgical oncology
  16. Integrated Analyses of m6A Regulator-Based Signature on Its Clinical Application and Immunogenomic Landscape in Stomach Adenocarcinoma.2022BioMed research internationalFree full text
  17. Impact of sarcopenia on clinical outcomes of patients with stage I gastric cancer after radical gastrectomy: A prospective cohort study.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Chinese and Global Burdens of Gastrointestinal Cancers From 1990 to 2019.2022Frontiers in public healthFree full text
  19. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.2022Neoplasma
  20. Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach.2021Current molecular medicine
  21. Development and validation of nomograms for the prediction of low muscle mass and radiodensity in gastric cancer patients.2021The American journal of clinical nutrition
All its trials on ClinicalTrials.gov, any status4
  1. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric CancerRecruitingNCT07366528Study sitePhase 3Start 2025-12
  2. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  3. Safety and Efficacy of NK510 to Treat Gastric CancerStatus unknownNCT06098898Study siteEarly phase 1Start 2023-11
  4. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

8 hospitals in Shanghai for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. The Sellar Tumor: Metastasis or Chordoma?2018The Journal of craniofacial surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 20 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 2220232024: 4420242025: 552025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led20
  1. Ion interference induced by Ca-Mn nanoplatform enhances ferroptosis and promotes immune response for osteosarcoma treatment.2026Journal of advanced research
  2. Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. PDGFRB promotes dedifferentiation and pulmonary metastasis through rearrangement of cytoskeleton under hypoxic microenvironment in osteosarcoma.2025Cellular signalling
  4. Thrombospondin 1 Promotes Cytoskeleton Remodeling, Dedifferentiation, and Pulmonary Metastasis through ITGA1 and ITGA6 in Osteosarcoma.2025International journal of biological sciences
  5. Butyrate derived from intratumoral microbiome facilitates pulmonary metastasis in osteosarcoma.2025Pharmacological research
  6. Advances and challenges in the treatment of osteosarcoma.2025Progress in biophysics and molecular biology
  7. Photothermal Catalytic Reduction and Bone Tissue Engineering Towards a Three-in-One Therapy Strategy for Osteosarcoma.2024Advanced materials (Deerfield Beach, Fla.)
  8. Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis.2024Cancer science
  9. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.2024Clinical and translational medicine
  10. Real-world impact of chemotherapy on overall survival in craniomaxillofacial osteosarcoma.2024Journal of stomatology, oral and maxillofacial surgery
  11. (E)-SIS3 suppressed osteosarcoma progression via promoting cell apoptosis, arresting cell cycle, and regulating the tumor immune microenvironment.2023Drug development research
  12. Transfer of exosomal microRNAs confers doxorubicin resistance in osteosarcoma cells.2023Molecular medicine reports
  13. Photothermal-triggered immunogenic nanotherapeutics for optimizing osteosarcoma therapy by synergizing innate and adaptive immunity.2022Biomaterials
  14. LncRNA ODRUL regulates progression of osteosarcoma by regulating IL-6 via sponging miR-6874-3p.2022Experimental cell research
  15. Biomineralization-inspired synthesis of amorphous manganese phosphates for GLUT5-targeted drug-free catalytic therapy of osteosarcoma.2022Nanoscale
  16. Engineering Single-Atomic Iron-Catalyst-Integrated 3D-Printed Bioscaffolds for Osteosarcoma Destruction with Antibacterial and Bone Defect Regeneration Bioactivity.2021Advanced materials (Deerfield Beach, Fla.)
  17. LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p.2021BMC cancer
  18. Identification of 6 gene markers for survival prediction in osteosarcoma cases based on multi-omics analysis.2021Experimental biology and medicine (Maywood, N.J.)
  19. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.2021International journal of oncology
  20. Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes.2021JAMA network open
Earlier papers (2016–2020)28
  1. Is increased symptom interval associated with advanced stage and poorer outcome? A prospective multicenter study of 220 patients with osteosarcoma around the knee.2020Cancer epidemiology
  2. LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-Like polarization of tumor-associated macrophages of CPEB4.2020Cancer letters
  3. LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis.2020Cell death & disease
  4. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis.2020Journal of experimental & clinical cancer research : CR
  5. Tripartite Motif-Containing 46 Promotes Viability and Inhibits Apoptosis of Osteosarcoma Cells by Activating NF-B Signaling Through Ubiquitination of PPAR.2020Oncology research
  6. Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study.2019BioMed research international
  7. MiR-92a modulates proliferation, apoptosis, migration, and invasion of osteosarcoma cell lines by targeting Dickkopf-related protein 3.2019Bioscience reports
  8. Limb salvage for malignant bone tumours of distal tibia with dual ipsilateral vascularized autogenous fibular graft in a trapezoid-shaped array with ankle arthrodesis and preserving subtalar joint.2019Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  9. Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma.2019International journal of oncology
  10. Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells.2019Journal of cellular physiology
  11. Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance.2019Molecular therapy : the journal of the American Society of Gene Therapy
  12. Serine/Threonine Kinase 35, a Target Gene of STAT3, Regulates the Proliferation and Apoptosis of Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  13. Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing.2018Epigenomics
  14. A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma.2018International journal of biological sciences
  15. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1.2018International journal of biological sciences
  16. MicroRNA-18a inhibits cell growth and induces apoptosis in osteosarcoma by targeting MED27.2018International journal of oncology
  17. Survival, complications and functional outcomes of cemented megaprostheses for high-grade osteosarcoma around the knee.2018International orthopaedics
  18. MicroRNA-3200-5p Promotes Osteosarcoma Cell Invasion via Suppression of BRMS1.2018Molecules and cells
  19. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2.2017Cancer letters
  20. MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  21. Antisense lncRNA FOXF1-AS1 Promotes Migration and Invasion of Osteosarcoma Cells Through the FOXF1/MMP-2/-9 Pathway.2017International journal of biological sciences
  22. Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.2017Journal of cellular and molecular medicine
  23. Shikonin promotes adriamycin‑induced apoptosis by upregulating caspase‑3 and caspase‑8 in osteosarcoma.2017Molecular medicine reports
  24. [Sensitivity of doxorubicin-resistant osteosarcoma cells to doxorubicin regulated by long non-coding RNA NR_036444].2017Zhonghua zhong liu za zhi [Chinese journal of oncology]
  25. MiR-329 suppresses osteosarcoma development by downregulating Rab10.2016FEBS letters
  26. Benzochloroporphyrin derivative photosensitizer-mediated photodynamic therapy for Ewing sarcoma.2016Journal of photochemistry and photobiology. B, Biology
  27. SOX18 knockdown suppresses the proliferation and metastasis, and induces the apoptosis of osteosarcoma cells.2016Molecular medicine reports
  28. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Benzochloroporphyrin derivative photosensitizer-mediated photodynamic therapy for Ewing sarcoma.2016Journal of photochemistry and photobiology. B, Biology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskKidney & bone complications

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海市第十人民医院

Shanghai Tenth People's Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Shanghai Tenth People's Hospital of Tongji University; Shanghai Tenth People's Hospital Affiliated to Tongji University; Tenth People's Hospital of Tongji University; Shanghai Tenth People's Hospital & Putuo District People's Hospital; Shanghai Tenth Peoples' Hospital affiliated Tongji University; Shanghai Tenth People' s Hospital; Shanghai Tenth Peoples' Hospital; Shanghai Tenth People's Hospital Tongji University

Suggest a correctionDownload the data